Search Results
Investigating Design Aspects of Immersive Virtual Field Trips and Site Experiences
This study investigates the effects and effectiveness of different options for designing immersive virtual reality tours of real-world places. Participants will wear a Virtual Reality headset and watchseveral short tours featuring different environments (museum, forest, harbor, Mayan site). After each tour, participants will be asked for their opinion on certain design aspects of the tour app.
English speaking
able to wear a VR headset + sit and turn in a swivel chair while watching the short VR tours
able to listen to the tour's audio commentary
non-English speaking
Trust in Realistic Situations
We are exploring how a robot's competence, benevolence and integrity influence one's decision to rely on a robot and accept its guidance. We're also exploring different ways to interact with robot using virtual reality and in person experimentation.
Able to complete the consent form
Able to see
Individuals that have uncorrected seeing difficulties that would prevent them from being able to complete the survey will be excluded
Cardiovascular Effects of Angiotensin 1-7 in Obesity Hypertension
The purpose of this study is to see if the hormone angiotensin-(1-7) lowers blood pressure and sympathetic activity and improves the function of blood vessels and in obese subjects with hypertension.
This is an outpatient study that requires a screening visit, and if eligible, two study visits in the Clinical Research Center within the Penn State Health Milton S. Hershey Medical Center. The screening visit will take about one hour and includes a brief physical examination and medical history, a urine pregnancy test if female and of childbearing potential, measurement of heart rhythm, collection of blood samples, and measurements of body composition. If eligible based on the results of the screening visit, participants will be invited to participate in two study visits that are about four hours and are separated by at least one week. Participants will complete food recall and activity questionnaires prior to each study visit. A urine pregnancy test will be given for females of childbearing potential. Participants will lie down on a bed and a catheter will be placed in a vein in each arm to draw blood samples and to give study medications. Equipment will then be placed to measure heart rate, blood pressure, and the amount of oxygen in the blood. A blood pressure cuff on the arm will be inflated for up to five minutes to measure blood flow in the arm using ultrasound and blood samples will be collected. Small electrodes will then be inserted into a nerve and just under the skin on one leg to measure nerve activity, which will remain in place until the end of the study. Participants will then receive either angiotensin-(1-7) or normal saline through the catheter in the arm for up to 120 minutes. Angiotensin-(1-7) is a substance that the body produces naturally; however, in this form, it is considered experimental, which means the Food and Drug Administration has not approved it for this use. Participants will receive angiotensin-(1-7) at one study visit and normal saline at the other study visit. The treatments will be randomly assigned so that the order in which they receive each treatment will be determined purely by chance, and neither the participant nor study investigators will know which treatment is received at each study visit. Blood pressure, heart rate, oxygen in the blood, and leg nerve activity will be measured continuously while giving angiotensin-(1-7) or normal saline. Near the end of treatment, blood flow in the arm will be measured again. At the end of the last dose, another blood sample will be taken. Participants will then be allowed to recover for at least 20 minutes and then all equipment will be removed. After the study visit, participants will be asked to complete a questionnaire if they had the nerve activity measurements, and a nurse will contact them to check on general well-being and answer any questions.
$25 per hour
Obesity (defined as body mass index between 30-40 kg/m2)
Hypertension (defined as seated blood pressure greater than 130/80 mmHg)
Able and willing to give informed consent
Fluent in written and spoken English
Current smokers
Type I or type II diabetes
History of major cardiovascular disease, immune or liver diseases, impaired renal or liver function
Morbid obesity (body mass index greater than 40 kg/m2)
HERMES: Effects of ziltivekimab versus placebo on morbidity and mortality in patients with heart failure with mildly reduced or preserved ejection fraction and systemic inflammation.
To see how ziltivekimab taken once monthly versus placebo, both added to standard of care, in reducing the risk of cardiovascular death and heart failure events in participants with heart failure iwht mildly reduced or preserved ejection fraction and systemic inflammation.
Return for on site visits 14 times, participate in 6 phone calls, complete questionnaires, blood samples taken at each on-site visit, electrocardiogram completed on 5 visits, injection of study medication.
approximatley $1,120
age 18 years or above
unstable medical therapy for heart failure
active hepatitis C
pregnant females or females not using effective contraceptive
How Does the Intersection of Gender and Language Affect Stigma in Opioid Use Disorder?
This research experimental study aims to investigate the impact of gender and language on stigma related to opioid use disorder (OUD) among college students. Participants, aged 18 and older, will be randomly assigned to read vignettes describing individuals with OUD, varying in gender and language use. After reading, participants will complete a brief survey assessing their perceptions of stigma associated with OUD. The study seeks to uncover how stigmatizing language and gender-specific societal expectations interact to shape attitudes, contributing to a better understanding of OUD stigma in the college-aged population.
Participants will engage in a structured series of activities. Initially, they will complete a demographics questionnaire, providing essential information such as age, gender, and college affiliation. Subsequently, participants will be presented with one of four vignettes designed to systematically manipulate language and gender variables related to OUD stigma. Following the vignette exposure, participants will respond to The Perceived Stigma of Substance Abuse Scale (PSSAS) as part of the survey.
18 years or older
Not a college student
Validation of Cell-free mitochondrial DNA (cf-mtDNA) Saliva Collection Methods
The reproducibility, reliability, and validity of saliva collection techniques is an important issue that needs to be addressed to achieve consistency in the emerging field of mitochondrial psychobiology. The objective of the current study is to increase scientific rigor by utilizing robust and well-controlled methods in the collection and testing of saliva samples. Given the non-invasive and convenient nature of saliva collection, it is likely that research using saliva-derived cell-free mitochondrial DNA (cf-mtDNA) will increase. Therefore, to ensure that the results obtained from the current study are trustworthy and meaningful, we are proposing a small, highly controlled randomized study design that will integrate three methods of saliva collection. The study will adopt a rigorous and systematic approach to data collection, analysis, and interpretation. Through the implementation of these methods, we seek to achieve a higher degree of accuracy and reliability in cf-mtDNA saliva-based measurements.
Each participant will be asked to collect 3 randomized saliva samples (i.e., one static Salivette®, one active Salivette®, and either a second active Salivette® or a passive drool) upon awakening for 10 business days. All collection materials be pre-labeled with the day, type of sample, and order to make it easy for participants to quickly and accurately deposit samples upon awakening. Once saliva samples are collected, participants will be asked to promptly return the samples to the provided plastic bag and store the bag in their at-home freezers. All samples will be stored there until the end of the 10-day study. After the saliva is returned to the freezer, participants will complete a short (3-5 min) morning survey on the provided mobile device which has been pre-loaded with the M2C2 application. The morning survey asks questions about sleep, morning outlook, and anticipatory stress and positive experiences. In the evenings, participants will be prompted (via banner notification on screen and audible beep) to complete a slightly longer (8-10 min) survey. This survey asks questions about the respondent’s daily experiences (stressors, mood, physical symptoms). Within the application, there are three brief, objective cognitive tasks. Upon completion of the 10-day protocol, respondents will return the mobile device and saliva samples. Participants may bring all saliva samples back to the lab during regular business hours, or they may schedule a time for a member of the study team to pick up the samples. Depending on the distance between the laboratory and the participant’s home, the need for ice packs will be assessed on an individual basis.
50
between the age of 18-50 years
must be English speaking
cannot be pregnant or breastfeeding
must not use tobacco
Individuals who work nightshift
Individuals who do not have access to an at-home freezer
Individuals who have an irregular sleep-wake cycle
Individuals who currently use tobacco
PSCI 22-082 Tropion-Breast03
This is an investigational drug study comparing the Investigational treatment with treatments called capecitabine and pembrolizumab as stand-alone treatment agents or in combination. Study participants will be required to attend all study visits, complete the tests and procedures, receive study treatment, and complete questionnaires.
Participants must attend all visits, receive study treatment, have blood drawn, complete questionnaires, have imaging scans done (ECG, ECHO or MUGA, CT, mammogram or breast MRI), keep a diary, have an eye exam, and provide a tumor sample.
Histologically confirmed invasive TNBC.
Residual invasive disease in the breast and/or axillary lymph node(s) at surgical resection following neoadjuvant therapy.
Completed at least 6 cycles of neoadjuvant therapy containing an anthracycline and/or a taxane with or without carboplatin, with or without pembrolizumab.14
No evidence of locoregional or distant relapse. Radiological scans before treatment are not required and should be obtained as per local institutional practice.
History of prior invasive breast cancer, or evidence of recurrent disease following preoperative therapy and surgery.
As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including history of allogeneic organ transplant and active bleeding diseases, ongoing or active infection,
History of another primary malignancy except for adequately resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin, in situ disease that has undergone potentially curative therapy
Persistent toxicities caused by previous anticancer therapy, excluding alopecia, not yet improved to Grade ≤ 1 or baseline.
An Examination of Student-Mentor Relationships
This is a self-report survey and questionnaire study that examines whether members of marginalized groups are more motivated than members of dominant groups to give referent power to high status others in attempts to belonging.
All races/ethincities
Participants between 18 and 25
Participants OLDER than 25
Return to Work Survey Development for Breast Cancer Survivors
The purpose of this study is to develop and test a survey to gain information that will improve our understanding of the return to work experience for breast cancer survivors. Study participants will answer questions on a questionnaire and undergo a one-on-one interview about those questions to ensure the wording and content is appropriate.
This is a questionnaire development study. Participants will be asked to complete a series of questions on a questionnaire form. Next, participants will sit for a one-on-one interview to discuss the questions and answer choices on the questionnaire.
Last cancer treatment was 2-5 years ago
Received breast cancer treatment at Penn State Health
Employed outside the home at least part time (>20hr/wk) before and after cancer treatment
Underwent prophylactic treatment due to increased risk, such as testing positive for BRCA gene (breast cancer)
Unemployed or does not participate in the workforce for pay either before or after cancer
Currently being treated for any type of cancer
Has experienced a work-related injury that does not allow work, is receiving Worker's Compensation, or is currently in litigation for work-related injury
22-111 A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
This study involved testing a drug for the treatment of relapsed/refractory multiple myeloma. The trial consists of three parts: the first part looks at the safety of the drug when given to patients; the second and third part looks the dose of the drug at how the drug is used through the body and how it acts on multiple myeloma.
Participants will need to attend the scheduled visits, provide medical history, blood samples, complete questionnaires, radiology exams, bone marrow aspirate and/or biopsy, and take study medication
Aged 18 years or older.
For patients in Parts 2 and 3 only: Measurable disease defined as one of the following: a)Serum M-protein ≥500 mg/dL (≥5 g/L).
During Part 1 only, patients not meeting the above criteria for measurable disease should, at least, have measurable bone marrow plasmacytosis (≥10%) and/or plasmacytoma (≥1 cm in diameter) detected by physical examination or imaging.
ECOG performance status of ≤2.
Patients who have received autologous SCT 60 days before first infusion of modakafusp alfa or patients who have received allogeneic SCT 6 months before first infusion.
Graft-versus-host disease that is active or requires ongoing systemic immunosuppression.
Part 1: Until the MTD/OBD is defined, patients who have received daratumumab (or other investigational anti-CD38 antibody) for at least 5 months (steady state) require a 90-day wash-out period before receiving modakafusp alfa.
Patient has not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE Grade ≤1 or baseline,
Minoritization and transnational social hierarchies: Caste and race in the Indian immigrant context
The study looks to understand how caste and race play out among Indian students, especially Indian immigrant students. Caste is the predominant social category in India. However, as Indian students migrate into to the USA, the social category of race is introduced and social category of caste is not understood outside of the Indian community. Through qualitative interviewing, it is aimed in this study to determine how migrating to the USA and becoming a minority and a person of color can potentially change how Indians view caste and caste identities in India. The primary hypothesis of the study is that the process of becoming becoming a minority through immigration can be used to think back on caste, and to think forward on race in both India and the USA.
Citizen/Resident of India for at least 5 years OR one or both parents have been citizens of India for at least 5 years
Students/Faculty members at Penn State
Subjects who do not speak English
The effect of repetitive thinking on emotional reactivity to daily events in depression and generalized anxiety disorder: Application of the contrast avoidance model
This is an ecological momentary assessment study that will examine the relationship between daily events, emotion, and repetitive thinking using a mobile application. The participants will be required to answer 2 minutes questionnaire and monitor their heart rate 8 times a day for 8 consecutive days.
If you are eligible based on the screening survey, there will be one Zoom study session where you will complete a brief videotaped clinical interview to further determine your eligibility to participate in the study. If you are eligible and decide to continue in the study, you will complete a brief questionnaire and be trained on how to complete the study. Starting the next day, you will complete eight 2-minutes questionnaires per day and monitor your heart rate using smartphone application for 8 days.
Up to $20 (Amazon gift card)
Owns iPhone.
Scores high or low on depression and anxiety symptoms measure
Fluent in the English language in terms of speaking, listening, reading, and writing
Meets diagnostic criteria for bipolar disorder or schizophrenia-related disorders
Has suicidal thoughts
Unable to speak, read, listen, and write English fluently.
PACE – Development of an Eating Behavior Risk Score
The prevention of obesity is a far more effective approach than treating obesity after it has developed. Researchers and medical providers need better tools to identify risk factors for developing obesity, so families and their physicians can work to reduce a child's risk. This proposed study tests whether a novel risk score (PACE) is good at predicting if children will develop obesity. The PACE Score combines the measures of sensitivity to portion size, behavior while hungry or craving, loss of control during eating, and eating speed. This study will follow children in middle childhood through four visits, followed by two visits one year later. We will identify the components of PACE as well as biological and environmental factors that may work with or against the PACE factors to predict how children's body composition changes over a year.
Four baseline visits followed by two follow-up visits one year laterChildren will be provided meals at each visitChildren and parents will complete questionnairesChildren will have a DXA scan and an MRI scanChildren will play learning games on the computerChildren will wear an activity monitor for one weekChildren will perform brief and moderate exercise while wearing a heart rate monitor
$300
The biological mother must have a BMI between 18.5 – 25 or greater than 30. The parent primarily in charge of feeding must be able to accompany children to the visits.
children must speak English fluently
children should have no learning disabilities or developmental delays (e.g., ADHD, Autism, dyslexia)
children generally healthy with a BMI-for-age percentile less than 85 or greater than 95 to be enrolled.
Child medical condition affecting digestion, cardio, etc.
Child not fluent in English
Child should not be taking a medication that affects blood flow, appetite, behavior, etc.
Child should not have any unremovable metal in their body (e.g. steel dental work) or be claustrophobic
A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation Following Curative Resectionfor Stage I Non-small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm:Big Ten Cancer Research Consortium BTCRC-LUN18-153 (PSCI# 20-043)
This is a research study to find out if giving a drug called pembrolizumab after lung cancer surgery does a better job at keeping the cancer from coming back than surgery alone. The usual approach for patients who are not in a study is to be followed closely by their doctor to watch in case the cancer returns. Participants in this study will be assigned by chance (flip of a coin) to be watched closely by their doctor or to receive a drug called pembrolizumab. Pembrolizumab is given as an infusion inthe clinic once every six weeks. . You will have tests, exams and procedures that are part of your regular care and for study purposes. You will have scans every 12 weeks to make sure the cancer hasn’t come back. If you are assigned to receive pembrolizumab, you can continue to receive it for up to 1 year.
If you decide to take part in this study, you will be assigned to one of two groups. This is called randomization. A computer will assign you to a group in the study by chance. This is done by chance because no one knows if one study group is better or worse than the other. You will have an equal chance (50/50) of being assigned to either group.
Patients must have undergone complete surgical resection of their stage I non-small cell lung cancer between 4-12 weeks prior to registration.
Pathological tumor size must be 1.0 – 4.0 cm in size.
ECOG Performance Score 0-1
Baseline CT chest must be performed within 28 days of randomization
No prior PD-1 or PD-L1 inhibitors are permitted.
No prior neo-adjuvant or adjuvant chemotherapy is permitted for this lung cancer.
Patients with a history of (non-infectious) pneumonitis that required steroids
Has active autoimmune disease that has required systemic treatment in the past 2 years.
Personality Pathology in Youth
In this study, we hope to better understand the neural mechanisms underlying risk for personality disorders in adolescent youth. Understanding who is at risk for personality disorders early in development is important in order to develop preventative interventions.
Youth participants and their parent will be required to attend one in-person visit at our lab in Hershey, PA where youth participants will complete two computer tasks while EEG and cardiac data are collected. Youth participants will also complete questionnaires and a peer-interaction task with another peer their age. Parents will complete questionnaires and an interaction task with their child. Youth participants will complete remote surveys via a survey app for two weeks after the visit. This study includes 4 follow-up appointments (once every 6 months) which can be completed in-person or remotely via a Microsoft Teams meeting. These follow-up appointments will consist of a parent-child interaction task and surveys for parent and youth participants.
Up to $305
Current or past history of a mental health disorder OR no history of mental health disorder
Fluent in English
Youth or parent not fluent in English
Youth with intellectual or development disabilities
Youth with schizophrenia, bipolar disorder, or other psychotic disorders
Couples' Daily Lives with Chronic Back Pain
The purpose of this study is to learn more about the daily experiences of people with back pain and their spouse/partner. Participants and their spouse/partner will be interviewed by video using a tablet computer every 6 months for 2 years and will be asked to complete daily surveys twice a day for 30 days using the provided tablet computer. The daily surveys will take about 5 to 10 minutes to complete. Questions for the interviews and daily surveys focus on physical symptoms, feelings, activities, and interactions.
Video interviews using a tablet computer every 6 months for 2 years. Complete daily surveys twice a day for 30 days using a tablet computer.
295.00
Experienced moderate or severe back pain for at least 3 months
Married or in a long-term relationship AND living with spouse or partner
Remote testing for psychophysical studies of sensory perception and cognition
The purpose of this study is (1) to understand how the brain processes sensory information and (2) how this is affected by factors like blindness or synesthesia.
Participants will complete simple online tasks, for example judging differences in auditory pitch; processing visual and auditory stimuli in congruent and incongruent pairings; rating the sound-symbolic properties of either real words, pseudowords, or both; or discriminating between two stimuli on the basis of their structural properties over a change in their surface properties, and vice versa.
Amount varies depending on the study
Normal or corrected-to-normal vision
No other sensory deficits
Adults who experience synesthesia
PSCI# 24-028 NRG-BR008: A PHASE III RANDOMIZED TRIAL OF RADIOTHERAPY OPTIMIZATION FOR LOW-RISK HER2-POSITIVE BREAST CANCER (HERO*)
This study will look at the differences in recurrence between patients who receive breast radiation after surgery to those who don't.
Participants will be required to come to all study visits, complete their radiation and chemotherapy treatments.
The patient must have an ECOG performance status of 0 ,1,
Histologically or cytologically confirmed invasive breast carcinoma.
The tumor must have been determined to be HER2-positive by current ASCO/CAP guidelines based on local testing results.
The tumor must have ER and PgR status assessed locally using current ASCO/CAP Guidelines.
patients with a primary tumor >2 cm on pathologic examination of the surgical specimen
Patient planning for or status-post mastectomy.
Non-epithelial breast malignancies such as sarcoma or lymphoma.
Multicentric carcinoma (invasive cancer or DCIS)
Pattern Learning in Human Adults
We are interested in what adults notice about stimuli that are presented to them. These stimuli typically consist of novel objects, abstract images, or made-up words.
Fluent in English
Minimum High School Education
Normal or corrected-to-normal vision/ hearing
Those unable to consent, pregnant women, children, and prisoners will be excluded.
fMRI based mapping of the supraspinal projections of the exercise pressor reflex
This study will examine how the brain controls blood pressure responses during exercise, and will include 2 separate visits. In one visit, you will perform a series of handgrip exercises followed by inflation of a blood pressure cuff while we collect muscle nerve activity and blood pressure. In the other two sessions you will perform a similar task while laying in an MRI machine.
healthy
able to perform handgrip execise
normal blood pressure
have metal implants
taking heart medication
pregnant/nursing
smoker
Exploring Gender Differences in ADHD Through Narrative Competency
This is an interview study that will examine how people with and without ADHD tell stories. Eligible participants will be asked to attend a virtual televisit where they will tell three stories according to prompts given by study staff. We are recruiting both men and women for this study so we can determine if gender affects storytelling ability.
There will be one virtual visit on Zoom lasting approximately one hour. Participants will complete eligibility questionnaires, then eligible participants will be asked to tell three stories based on prompts from an investigator and complete one additional questionnaire.
$15
Diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD)
No diagnosis of Attention-Deficit Hyperactivity Disorder (ADHD)
Native English speaker
Under 18 or over 30 years old
Psychosis, dyslexia, or other neurological impairment
Uncorrected hearing loss
Defining the role of slow eye movements on limb motor control
The purpose of this study is to define how eye movements contribute to eye-hand coordination. All procedures to be used in our study will be non-invasive. The task during the study will be performed with a robotic handle that participants will grasp with their right hand. They will interact with visual stimuli by moving the robotic handle. The robotic environment will attempt to simulate real-world mechanical interactions, such as those experienced during catching a ball. Our objective is to understand how the nervous system processes visual sensory information of moving objects through slow eye movements called smooth pursuit eye movements.
During this study, we will ask you to come to our laboratory located in 23 Recreation Building, Penn State University, on two days separated by a maximum of 48 hours. Both sessions will last approximately 90-120 minutes.We will ask you to perform an eye-hand coordination task using a robot. You will sit in a modified chair and grasp a handle that permits you to move your hand leftward, rightward, towards and away from your body. A display system will project visual targets into the same plane as your hands, which will allow you to interact virtually with the visual targets. These targets will move in the workspace. When the target comes in contact with your arm, the robot will apply a gentle force to mimic what you would typically experience when you catch a ball.
40
Male and female participants who volunteer for the study and provide informed consent.
Participants will be right-hand dominant individuals.
They will have normal or corrected-to-normal vision.
Participants should be able to sit upright in a chair for long periods (up to 2 and a half hours) with rest.
Any history of musculoskeletal disorders.
Eye or vision problems.
Cognitive impairment such that informed consent cannot be obtained, or that participant would not be safe with the protocol.
Medication that could make the participant drowsy or tired during the experiment.
Understanding the user experience of using consumer-facing digital symptom checkers
This is an interview study that examines how people use online symptom checker platforms or apps (e.g., WebMD, Ada, K health app, Your.MD) to self-diagnose or support the decision of whether and when to do a medical visit. The research procedure involves: 1) a short screening survey which helps us determine who are eligible to participate; 2) an audio‐taped interview with each eligible participant that will last approximately 30‐60 minutes online or offline near Penn State University Park. Each participant will be compensated with a $20 Amazon gift card for completing the interview.
Speak English or Chinese
At least 18 years of age
Have used online symptom checker platforms or apps
Have never used any symptom checker
Vulnerable populations such as children, pregnant women, cognitively impaired adults, and prisoners
Decision-Making in ADHD: An Evaluation of the Subjective Value of Rewards and Costs
Children with attention and behavior problems often need external rewards to motivate them to perform challenging tasks, but we don’t yet know much about how children weigh potential rewards and the effort required to obtain the rewards. This research is being done to find out how children with varying levels of ADHD symptoms value rewards and costs when making decisions about whether or not to perform a difficult task.
There will be one in-person visit. Children will complete two computerized cognitive tasks (thinking games), and will be able to earn prizes from the points they earn on these tasks. Parents will also be asked to complete a few questionnaires that should take about 25 minutes to finish. Children can earn up to $50 in compensation for completing the study.
$50
Children with normal or corrected vision
Caregiver and child must be fluent in written and spoken English
Willing to stop stimulant medications, when appropriate, for research testing
Current or past diagnosis of autism spectrum disorder, schizophrenia or other psychotic disorders.
Current use of non-stimulant medication due to its extended washout period.
Physical disabilities that are incompatible with completing laboratory tasks such as hearing impairments, or visual impairments that cannot be corrected with visual aids (i.e., glasses, contacts).
Saliva microRNA signatures in infants with wheezing associated respiratory illness
Wheezing is a common symptom of respiratory distress in infants and children. Infants who wheeze are at increased risk of being diagnosed with asthma, the most common chronic disease of childhood. This study aims to yield an objective measure of asthma risk using molecular markers obtained from saliva. Saliva miRNA (markers used in this study) levels will be measured using HiSeq technology. Refinement and validation of this measure in future large-scale studies could allow clinicians to accurately predict for families an infant’s risk of asthma and optimize medical management to prevent future hospitalizations.
If your child has a respiratory illness you will be asked to provide a saliva sample at one clinic visit. Six months after the initial encounter, you will be asked to do complete surveys designed to be done remotely at home.
$20.00
Presence of respiratory illness symptoms (cough, congestion, shortness of breath, runny nose)
Concurrent pneumonia (bacterial lung infection) at the time of enrollment
Bronchopulmonary dysplasia
Concurrent bacterial infection requiring antibiotics (e.g. otitis media)
PHASE I SAFETY ASSESSMENT OF HYPOFRACTIONATED POSTOPERATIVE RADIOTHERAPY (H-PORT) FOR INTERMEDIATE-RISK HEAD AND NECK CANCER
The purpose of this study is to test the good and bad effects of using hypofractionated radiation therapy. Hypofractionated radiation therapy could shrink or stabilize your cancer, but it could also cause side effects. The study doctors hope to learn if hypofractionated radiation therapy is safe and tolerable in patients with your type of cancer. You will receive radiation therapy for 4 weeks. You may also receive chemotherapy.
Participants will be required to receive radiation therapy for 4 weeks. Participants may also receive chemotherapy with cisplatin, carboplatin, or cetuximab.
Clinical stage II, III or IVA squamous cell carcinoma of the oral cavity, oropharynx or larynx (AJCC 8th edition), including no distant metastases.
Total resection of the patient’s cancer (i.e. no residual disease after total resection of the patient’s cancer ).
One or more indications for postoperative radiotherapy, based upon pathologic findings: • Perineural invasion; • Lymphovascular invasion;
Zubrod Performance Status 0-1
History of systemic lupus erythematosus or systemic sclerosis (scleroderma).
Pregnancy and individuals unwilling to discontinue nursing.
Feeding tube (gastric or jejuno) at the time of registration.
Anticipated need for high-dose systemic chemotherapy (e.g. high dose q3-week cisplatin), multiple systemic therapy agents or immunotherapy. Weekly single-agent systemic therapy with cisplatin, carboplatin, or cetuximab is allowable.
PSCI 23-092 EA8192 A Phase II/III trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy
This trial is comparing outcomes of cisplatin eligible vs cisplatin ineligible high grade urothelial cancer patients treated with accelerated therapy vs gemcitabine and durvalumab followed by surgery.
Participants will need to complete all study visits, agree to having surgery and to make sure to tell the study team if they are having any side effects.
Patient must have the ability to understand and the willingness to sign a written informed consent document
Patient must have a diagnosis of high grade upper tract urothelial carcinoma proven by biopsy
Patients must not have any component of small cell/neuroendocrine carcinoma
Patients must not be pregnant or breast-feeding
Patient must not have another active (or within two years) second malignancy
Patient may have a history of resectable urothelial cancer
Patient must not have any uncontrolled illness
Patient must not have received prior systemic anthracycline therapy
Cognitive and Social Factors Underlying Spoken Language Use
The central purpose of this research is to understand how language users produce and comprehend speech. To do this we ask participants to record speech, make judgments on the speech they hear, and work with a partner on simple language tasks.
Between 18 and 65 years of age
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE)
Repotrectinib for cancer that has returned or is not responding to treatment
If you agree to take part in this study, you will need to visit the study site regularly and follow the study procedures listed later in this document. You will be told what these procedures are and why they are needed. These procedures include interviews, exams, heart testing, tumor assessments, and blood and urine samples. You will be asked to take the study drug Repotrectinib. This is a capsule to be taken orally.
You are positive for certain changes in your genes which we will test you for as needed
A Phase 2, Double-Blind, Placebo-Controlled Trial of Mycophenolate Mofetil alone or with Voclosporin for Systemic Lupus: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment
Treatment of Systemic Lupus with mycophenolate mofetil alone or with voclosporin
There will be 16 visit over a years time, physical exam, blood work, ECG, questionnaires
Systemic Lupus